


 Cite this: *RSC Adv.*, 2021, **11**, 19248

# Effective inhibition and eradication of pathogenic biofilms by titanium dioxide nanoparticles synthesized using *Carum copticum* extract†

 Mohammad Altaf,<sup>ad</sup> Mohammad Tarique Zeyad,<sup>id</sup>\*<sup>b</sup> Md Amiruddin Hashmi,<sup>c</sup> Salim Manoharadas,<sup>id</sup><sup>d</sup> Shaik Althaf Hussain,<sup>d</sup> Mohammed Saeed Ali Abuhasil<sup>e</sup> and Mohammed Abdulaziz M. Almuzaini<sup>d</sup>

Most bacteria exist in nature in the form of biofilms. One of the key survival strategies by bacteria to withstand chemical and physical stresses is by forming biofilms on biotic and abiotic surfaces. A different set of genes are expressed in biofilms compared to the planktonic mode of bacterial growth. According to data from the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), nearly 80 percent of all human infections are encouraged by biofilms and roughly 65 percent of all hospital-acquired infections are associated with biofilms. Hence, considering the role of biofilms in clinical settings, there is an urgent need for the discovery/development of novel antibiofilm agents. In this study, we have tested the effect of freshly prepared titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs) synthesized using *Carum copticum* extract on biofilms, both against Gram +ve and Gram -ve bacteria. Being environment friendly in nature, the green route of nanoparticle synthesis is believed to be advantageous over chemical synthesis of metal nanoparticles. The synthesized nanoparticles were found to be predominantly spherical or spheroidal in shape with an average size of 12.01 ± 5.58 nm. As evident from data, more than 70% inhibition of biofilms of test bacteria was achieved in the presence of TiO<sub>2</sub>-NPs. Electron microscopic analysis revealed that the adherence and colonization of bacteria on the glass surface were remarkably reduced by the treatment of TiO<sub>2</sub>-NPs. The EPS secretion of *E. coli* ATCC 25922 and *P. aeruginosa* PAO1 were inhibited by 62.08 and 74.94%, respectively. The EPS secretion of *S. aureus* MTCC 3160 was least inhibited (<55%) compared to other test bacteria. Moreover, TiO<sub>2</sub>-NPs successfully eradicated the preformed biofilms of *E. coli* ATCC 25922, *P. aeruginosa* PAO1, and *S. aureus* MTCC 3160 by 60.09, 64.14, and 48.30%, respectively. The findings demonstrate the efficacy of green synthesized titanium dioxide nanoparticles in inhibiting and eradicating the biofilms of bacterial pathogens and they may be further exploited for the development of a new alternative antibiofilm agent.

Received 13th April 2021

Accepted 19th May 2021

DOI: 10.1039/d1ra02876f

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

Earlier, it was thought that bacteria exist and grow in a free-floating form (or in planktonic mode) but later this concept was overturned by the discovery of biofilms.<sup>1</sup> Now it is widely accepted that the biofilm mode of bacterial growth is more predominant in nature,

industry, and clinical settings. Biofilms are also one of the key survival strategies in which bacteria can resist a number of chemical and physical stresses.<sup>2</sup> Briefly, biofilms are bacterial communities attached to abiotic or biotic surfaces that are enclosed in a self-produced polymeric matrix, composed of polysaccharides, proteins, and eDNA, termed as extracellular polymeric substances.<sup>3,4</sup> In biofilms mode of bacterial growth, there is an altered expression of certain phenotypes compared to the planktonic counterparts.<sup>5</sup> For instance, bacteria in biofilms are more resistant to antibiotics and also to the host's immune response compared to planktonic bacteria.<sup>2,6</sup> It has been documented that *P. aeruginosa* growing as biofilms on urinary catheters were found to be 1000 times more resistant to tobramycin compared to the planktonic growth.<sup>7</sup> The enhanced resistance against antibiotics may also lead to the development of chronic infections such as cystic fibrosis, chronic wound infections, chronic-otitis media, etc.<sup>8</sup>

Biofilms have become a serious threat in the treatment of infection in clinical settings.<sup>9</sup> Apart from its role in chronic

<sup>a</sup>Department of Chemistry, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia

<sup>b</sup>Department of Agricultural Microbiology, Faculty of Agricultural Sciences, Aligarh Muslim University, Aligarh, UP-202002, India. E-mail: mohd.zeyad@gmail.com

<sup>c</sup>Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP-202002, India

<sup>d</sup>Central Laboratory, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

<sup>e</sup>Department of Food Science and Nutrition, College of Food & Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra02876f



infections, biofilms also develop on medical implants or devices, causing an extra burden on human health.<sup>10</sup> According to the National Institutes of Health (NIH) estimates, roughly 80 percent of all known infections in humans are linked to the development of biofilms. Moreover, the Centers for Disease Control and Prevention (CDC) has found that more than 65 percent of hospital-acquired infections are associated with biofilms.<sup>11</sup> The biofilms developed in persistent infections are difficult to be overpowered by the immune response of host.<sup>12</sup> Moreover, biofilms also induce enhanced overproduction of white blood cells and polymorphonucleocytes, resulting in chronic inflammation and ultimately causes complications in tissue and delay in wound healing.<sup>13</sup> Owing to the problems associated with biofilms in human health, the development of novel antibiofilm agents has become need of the hour.

In the last few decades, nanotechnology has received great attention in numerous disciplines of science such as materials science, biomedical engineering, medicine, *etc.*<sup>14</sup> Nanomaterials are typically less than 100 nm but sometimes its size may be more than 100 nm. Inorganic nanomaterials such as silver, gold, platinum, iron, titanium, zinc, *etc.*, are of great choice for biomedical applications in diagnosis, photo-thermal therapy, optical and electrical sensing, *etc.*<sup>15</sup> Furthermore, nanomaterials exhibit great implications for wound dressings, medical devices with anti-microbial properties, drug-eluting stents and, scaffolds to prevent biofilms.<sup>15</sup> Due to the ability of nanomaterials to inhibit bacterial growth and biofilms, continuous efforts are being made for the design and synthesis of nanoparticles with promising antibiofilm activities.

The most common procedure of metal nanoparticles is the chemical synthesis. In chemicals synthesis, certain chemicals are used for the reduction process to form metal nanoparticles in which these chemicals or their byproducts pose serious threat to environmental and biological systems.<sup>16</sup> The green route of nanoparticle synthesis has numerous advantages over chemical synthesis as it utilizes environment friendly materials (mainly natural extracts) without using harmful chemical entities.<sup>17</sup> Moreover, the biodegradability of natural products makes it advantageous and a commonly used material for synthesis of nanoparticles. The biological polymers such as starch, alginate, chitosan, cellulose *etc.* provide size confined microenvironment in which reduction of metal ions to form nanoparticles can be achieved through adsorption coupled reduction process.<sup>18</sup> However, there are certain limitations associated with the green synthesis. The major one is variations in phytochemical profile as it is influenced by seasonal or climate variations that may not remain precise enough to obtain reproducible results.<sup>19</sup> Additionally, there is also risk associated that overexploitation of natural resources may cause ecological imbalance of natural bioresources such as microbes and plants.

Titanium nanoparticles have been found to exhibit antimicrobial properties.<sup>20</sup> Moreover, there also some findings on the antibiofilm activity of titanium nanoparticles.<sup>19,21</sup> To the best of our knowledge, very limited reports are available on the broad-spectrum antibiofilm activity of titanium nanoparticles. Most of the previous findings do not considered the impact of nanoparticles on the biofilm's architecture. Considering the lack of information available in these aspects, titanium dioxide

nanoparticles (TiO<sub>2</sub>-NPs) were synthesized using aqueous extract of *Carum copticum* and characterized using spectroscopic and microscopic techniques. The nanoparticles were tested for its efficacy to inhibit the biofilms development of both Gram +ve and Gram -ve bacteria. The effect of TiO<sub>2</sub>-NPs on the biofilm's architecture was studied using light, confocal, and electron microscopy. Moreover, the ability of TiO<sub>2</sub>-NPs to eradicate the established biofilms of test bacteria was also explored.

## 2. Materials and methods

### 2.1. Chemicals and reagents

Titanium(IV) dioxide (GRM3065), acridine orange (MB116), and Luria Bertani Broth were purchased from HiMedia Laboratories, India. Crystal violet (074072) powder was procured from Sisco Research Laboratories (SRL) Pvt. Ltd.

### 2.2. Preparation of plant extract and synthesis of TiO<sub>2</sub>-NPs

Seeds of *Carum copticum* were purchased from the local market at Aligarh, UP, India. The seeds were powdered in the blender to prepare fine powder. Aqueous extract of plant material was made by suspending 50 g of the plant powder in 500 ml double distilled water. The mixture was boiled for 30 min in the water bath at 90 °C and then filtered using Whatman filter paper to obtain a clear solution.

For the synthesis of titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs), 20 ml extract was mixed with 300 ml of titanium(IV) dioxide (5 mM in double-distilled water) and mixed using a magnetic stirrer. One millilitre (1 ml) of 1 mM NaOH was added drop-wise in the reaction mixture while continuous stirring. The reaction was allowed to take place for 6 h at 60 °C. The nanoparticles were obtained by centrifugation at 13 500 rpm for 30 min. TiO<sub>2</sub>-NPs were washed three times with distilled water and then ethanol, and finally dried overnight in the oven at 50 °C. TiO<sub>2</sub>-NPs were stored at room temperature in powdered form for characterization and further studies.

### 2.3. Characterization of TiO<sub>2</sub>-NPs

Preliminary characterization of titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs) synthesized using aqueous extract of *C. copticum* seeds was performed using UV-vis spectroscopy. TiO<sub>2</sub>-NPs were suspended in double-distilled water and sonicated for 30 min. The UV-vis absorption spectrum of TiO<sub>2</sub>-NPs was recorded from 200 to 800 nm using UV-1800 spectrophotometer (Shimadzu, Japan). The baseline was corrected using double distilled water.

The diffraction pattern of TiO<sub>2</sub>-NPs was obtained using an X-ray diffractometer ranging from 20° to 80°. Cu-K $\alpha$  radiation with the nickel monochromator was used as the light source. The crystalline size of TiO<sub>2</sub>-NPs was calculated using Scherrer's eqn (1):<sup>22</sup>

$$D = \frac{K\lambda}{\beta \cos \theta} \quad (1)$$

where  $D$  is the crystalline size of TiO<sub>2</sub>-NPs;  $\lambda$  is the wavelength (1.5406 Å);  $\beta$  is full width at half maximum, and  $K$  is the constant for Scherrer's equation (0.9 to 1.0). The most intense peak (peak with the highest intensity) was used for the particle size calculation.

Fourier-transform infrared spectroscopy (FTIR) was used for chemical characterization as this tool deciphers the rotational



and vibrational modes of motion of molecules in TiO<sub>2</sub>-NPs. The nanoparticles were mixed with KBr in ratio of 1 : 100 to before recording the transmittance spectrum. The FTIR spectrum was recorded using Spectrum Two spectrometer (Perkin Elmer Life and Analytical Sciences, CT, USA) in diffuse reflectance mode at a resolution of 2 cm<sup>-1</sup> in the range of 4000 to 400 cm<sup>-1</sup>.<sup>23</sup>

For the analysis of size variation of shape of TiO<sub>2</sub>-NPs, transmission electron microscopy (TEM) was performed. The aqueous suspension of TiO<sub>2</sub>-NPs was placed on a TEM grid and air-dried overnight to prepare the grid. The TEM analysis was performed using a JOEL-2100 electron microscope (Tokyo, Japan) and micrographs were captured at 200 kV.<sup>24</sup> The elemental analysis of TiO<sub>2</sub>-NPs was performed by energy-dispersive X-ray (EDX) spectroscopy coupled to JEOL-JSM 6510 LV (Tokyo, Japan) at University Sophisticated Instrumentation Facility (USIF), AMU, Aligarh.<sup>25</sup>

#### 2.4. Bacterial strains and culture conditions

*Staphylococcus aureus* MTCC 3160, *Pseudomonas aeruginosa* PAO1, and *Escherichia coli* ATCC 25922 were used in this study. All cultures were grown in Luria Bertani (LB) broth at 37 °C otherwise stated. All the experiments were performed in LB broth C otherwise stated.

#### 2.5. Quantification of biofilms inhibition

The quantification of biofilm inhibition of test bacteria by TiO<sub>2</sub>-NPs was performed in 96-well polystyrene plate using standard crystal violet method with slight modifications.<sup>26</sup> TiO<sub>2</sub>-NPs were two-fold serially diluted (8–64 µg ml<sup>-1</sup>) in autoclaved Luria-Bertani broth. The bacteria were allowed to grow and inoculated in the wells containing varying concentrations of TiO<sub>2</sub>-NPs. No treatment was given to the control group. The microtitre plate was incubated for 24 h at 37 °C in static incubator. On completion of incubation period, the wells were decanted to remove media and washed with sterile phosphate buffer. The wells were air-dried for 20 min followed by the addition of 200 µl of 0.1% crystal violet to stain the biofilms. After 15 min, the crystal violet was removed and again washed with sterile phosphate buffer to remove unbound crystal violet. The plate was air-dried and finally, biofilms were dissolved in 200 µl ethanol (90% in distilled water). The absorbance of wells of polystyrene plate was recorded at 620 nm using microplate reader. The percent inhibition of biofilms was calculated with respect to the respective controls.

#### 2.6. Microscopic analysis of biofilm inhibition on glass surface

The inhibition of biofilms of test bacteria by TiO<sub>2</sub>-NPs was further studied using an array of microscopic techniques such as light microscopy, confocal laser scanning microscopy, and scanning electron microscopy.

**2.6.1. Light microscopy.** The test bacteria were cultured in the absence and presence of 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs in 24-well tissue culture plates. Sterile glass coverslips (1 cm × 1 cm) were placed in each well and the plate was incubated at 24 h for 37 °C. After incubation, the coverslips were removed from wells

and washed gently with sterile phosphate buffer to wash the loosely attached cells. The biofilms on the glass surface were stained with 0.1% crystal violet solution for 20 min. Excess amount of stain was removed by gentle washing and glass coverslips were air-dried at room temperature. The biofilms were visualized under a light microscope and images were captured at 40× magnification.<sup>27</sup>

**2.6.2. Confocal microscopy.** For confocal microscopic analysis of biofilms, the test bacteria were cultured in the absence and presence of 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs in 24-well tissue culture plates containing glass coverslips as mentioned above. Following incubation, coverslips were washed and stained with 0.1% acridine orange for 20 min and then air-dried at room temperature in dark. The biofilms were visualized using Zeiss LSM780 confocal laser scanning microscope at University Sophisticated Instrumentation Facility (USIF), AMU, Aligarh, and the images were recorded at 63× magnification.<sup>28</sup> The technical details of confocal microscopy are; pinhole size: 35.8, scanning speed: 5 frames per sec, objective lens: plan apochromat 63×/1.4 oil, scan time: 15.497 s, laser power: 1%, laser line: 488/543, detector type: Gallenium Arsenide Phosphide detectors (GaAsP), detection range: 504–557 nm, pixel size: 0.13 µm, image size: 134.8 µm × 134.8 µm, frame size: 1024 × 1024.

**2.6.3. Scanning electron microscopy.** For scanning electron microscopic analysis, the biofilms were developed in the absence and presence of 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs in 24-well tissue culture plates as mentioned above. After incubation, the glass coverslips were washed using sterile phosphate to drain loosely adhered bacterial cells. The biofilms present on the glass surface were fixed with glutaraldehyde solution for 24 h at 4 °C. The bacterial cells in biofilms were then dehydrated by washing with a gradient of ethanol ranging from 20 to 100%. Finally, the coverslips were air-dried and coated with gold. The biofilms were visualized under EOL-JSM 6510 LV scanning electron microscope at USIF, AMU, Aligarh.<sup>29</sup> The images were recorded at 2000× and 2500× magnification.

#### 2.7. Inhibition of exopolysaccharides

The level of exopolysaccharides (EPS) in control and TiO<sub>2</sub>-NPs treated cultures were assessed by following the standard procedure with minor modifications.<sup>30</sup> Briefly, the test bacteria were grown in presence of different concentrations of TiO<sub>2</sub>-NPs (8, 16, 32, and 64 µg ml<sup>-1</sup>) at 37 °C for 24 h. The control group was not given treatment. On completion of incubation period, bacterial cultures were centrifuged and cell-free supernatant was collected. Chilled ethanol was added to the culture supernatant in the ratio of 3 : 1 and the incubated overnight at 4 °C to precipitate the EPS. The level of EPS was determined by estimating the sugars using the Dubois method.<sup>31</sup>

#### 2.8. Disruption of mature biofilms

The biofilm disruption assay was performed in a 96-well polystyrene plate following the standard procedure with minor modifications.<sup>32</sup> The bacteria were grown in microtitre plates for 24 h at 37 °C to form the biofilms in the wells of microtitre pate. The media was then decanted gently and washed using sterile



phosphate buffer to remove loosely adhered cells. Freshly prepared media (Luria Bertani broth) was added to the wells of the plate and TiO<sub>2</sub>-NPs were added, making final concentrations of 8, 16, 32, and 64 μg ml<sup>-1</sup>. The polystyrene plate was incubated for the next 24 h under static conditions. The wells of plate were washed using sterile phosphate buffer to remove the planktonic cells. The biofilms were stained with crystal violet (0.1% solution in water) for 20 min. The stain was removed and gently washed. Finally, biofilms were dissolved in ethanol (90% in water). The absorbance was recorded using a microplate reader and percent disruption was calculated with respect to the control group.

## 2.9. Statistical analysis

The experiments were performed in three independent replicates and the data is presented as the average with standard deviation (SD). For the analysis of statistical significance, the analysis variance (One-way ANOVA) was performed by Tukey test at the significance level of 0.05. Different letters above each group of the independent variables show that the groups are statistically different from one another at *p*-value = 0.05.

# 3. Results and discussion

## 3.1. Synthesis and characterization of TiO<sub>2</sub>-NPs

The seeds extract of *C. copticum* was used for green synthesis of titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs). Being simple, usually one step, and ecofriendly in nature, green synthesis is advantageous over the chemical route of metal nanoparticle synthesis. One of the reasons for selection of this plant was that extracts of *Carum copticum* has been reported to exhibit antibiofilm properties.<sup>33</sup> It is expected that the combination of TiO<sub>2</sub>-NPs and phytoconstituents of *C. copticum* will impart enhanced antibiofilm action. Moreover, we have also reported the broad-spectrum antibiofilm and anti-quorum sensing activities of silver nanoparticles synthesized using *C. copticum* extract against Gram -ve bacterial pathogens.<sup>27</sup> TiO<sub>2</sub>-NPs were characterized using a number of spectroscopic and microscopic tools which are described below.

**3.1.1. UV-vis absorption spectroscopy.** The preliminary characterization of TiO<sub>2</sub>-NPs was performed by recording the UV-vis absorption spectrum. The TiO<sub>2</sub>-NPs exhibited a broad UV-vis absorption band in 385–395 nm as shown in Fig. 1A. The absorbance in this region is due to the formation of titanium

oxide nanoparticles.<sup>19</sup> The analysis of UV-vis absorption spectrum and λ<sub>max</sub> in this region is due to the presence of surface plasmons (SPR).<sup>34</sup> The finding is in agreement with the earlier report in which titanium dioxide nanoparticles synthesized using *Vitex negundo* extract exhibited absorption maxima in 380–400 nm range.<sup>35</sup>

**3.1.2. X-ray diffraction.** The crystalline nature of TiO<sub>2</sub>-NPs synthesized using *C. copticum* extract was studied using X-ray diffraction. The XRD pattern of TiO<sub>2</sub>-NPs is shown in Fig. 1B. The crystalline nature of TiO<sub>2</sub>-NPs was confirmed by diffractions at 25.473, 37.958, 48.205, 54.050, 55.208, 62.825, and 75.200°. These peaks confirm the crystalline titanium with anatase phase and it is also evident from the standard JCPDS database (21-1272).<sup>36</sup> The strong diffraction angle at 25.473 was related to (101) crystallographic plane of TiO<sub>2</sub> anatase only. The absence of unidentified peaks further confirmed the crystallinity and higher purity of the synthesized nanoparticles.<sup>37</sup> The crystal size of TiO<sub>2</sub>-NPs was calculated using Scherrer's equation and was found to be 14.462 nm. The finding corroborates with an earlier report in which titanium dioxide nanoparticles synthesized using *Mentha arvensis* leaves exhibited the strong XRD diffraction at 25.27 that was associated with (110) crystallographic plane.<sup>38</sup> This results further confirm that nanoparticles were monocrystalline and the sharp peaks show that the particles were in the nanoregime.<sup>39</sup>

**3.1.3. Fourier-transform infrared (FTIR) spectroscopy.** FTIR analysis was performed for chemical characterization of the synthesized titanium dioxide nanoparticles. The FTIR spectrum of TiO<sub>2</sub>-NPs ranging from 4000 to 400 cm<sup>-1</sup> is presented in Fig. 2. The intense transmittance bands within 1000 cm<sup>-1</sup> are due to the Ti–O–Ti vibrations,<sup>38</sup> confirming the linking of titanium with oxygen. Moreover, the band near 600 cm<sup>-1</sup> may be attributed to the O–Ti–O bond. The FTIR spectrum also exhibited characteristic bands at 1636 cm<sup>-1</sup> and 3414 cm<sup>-1</sup> that correspond to the hydroxyl groups and surface water.<sup>40</sup> The small crest at 1420 cm<sup>-1</sup> is linked to the vibration of O–H group of carboxylic groups. The overall shape of the FTIR spectrum of TiO<sub>2</sub>-NPs was found to be similar to the titanium dioxide nanoparticles that were synthesized using leaves extract of *M. arvensis*.<sup>38</sup> It has been documented that titanium dioxide nanoparticles synthesized using *Euphorbia prostrata* extract exhibited FTIR bands at 3420, 2926, 1377, 1071, 649, 2924 and 2926 cm<sup>-1</sup>.<sup>39</sup>




Fig. 1 (A) UV-vis absorption spectrum of titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs) synthesized using aqueous extract of *Carum copticum*. (B) X-ray diffraction (XRD) pattern of TiO<sub>2</sub>-NPs.






Fig. 2 Fourier-transform infrared spectroscopy (FTIR) spectrum of  $\text{TiO}_2$ -NPs. The spectrum was recorded from 4000 to 400  $\text{cm}^{-1}$  in diffuse reflectance mode at 2  $\text{cm}^{-1}$  resolution.

**3.1.4. Transmission electron microscopy (TEM) and EDX analysis.** The shape and size range of  $\text{TiO}_2$ -NPs was studied using transmission electron microscopy as shown in Fig. 3. As evident from the micrograph, most of the nanoparticles were spherical or spheroidal in shape. The nanoparticles were poly-dispersed and their size was less than 30 nm. The average particle size was found to be  $12.01 \pm 5.58$  nm. Moreover, the TEM image clearly shows that majority of the nanoparticles were below 20 nm in size. The elemental composition of  $\text{TiO}_2$ -NPs was studied using EDX analysis as presented in Fig. 3C. The analysis revealed that titanium and oxygen were the major constituents that constituted roughly 49% each. Nearly 1% carbon was also found in  $\text{TiO}_2$ -NPs that may be present on the surface and acting as a capping agent for the nanoparticles.

### 3.2. Antibiofilm activity of $\text{TiO}_2$ -NPs

Before evaluating the antibiofilm activity, test bacteria were grown in presence of  $\text{TiO}_2$ -NPs to assess its effect on the viable cells. The viability was determined by counting the number of colonies forming units (CFU). The number of viable cells of test bacteria in the absence and presence of 64  $\mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs is shown in supplementary Fig. S1.† This was the highest tested concentration at which insignificant ( $p$ -value > 0.05) difference in the viability of bacterial cell was recorded. Therefore, the antibiofilm activity was assessed at 64  $\mu\text{g ml}^{-1}$  and lower concentrations of  $\text{TiO}_2$ -NPs. The green synthesized nanoparticles were tested for its efficacy against the biofilms of *P. aeruginosa* PAO1, *E. coli* ATCC 25922, and *S. aureus* MTCC 3160. The findings are discussed below.

### 3.3. Quantification of biofilm inhibition by $\text{TiO}_2$ -NPs

The inhibition of biofilms by  $\text{TiO}_2$ -NPs against *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *E. coli* ATCC 25922 was quantified using crystal violet assay in 96-well microtitre plate. The data shows that  $\text{TiO}_2$ -NPs effectively reduced the biofilms of tested bacteria (Fig. 4). Treatment with 8, 16, 32, and 64  $\mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs inhibited the development of the biofilm of *E. coli* ATCC 25922 by 15.73, 23.19, 55.97, and 78.19%, respectively. Similarly, there was 11.03, 27.88, 42.60, and 70.67% reduction in biofilms of *P. aeruginosa* PAO1 in presence of 8, 16, 32, and 64  $\mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs. The biofilms of tested Gram +ve bacteria (*S. aureus* MTCC 3160) were maximumly inhibited by  $\text{TiO}_2$ -NPs. The addition of 8, 16, 32, and 64  $\mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs in culture media decreased the formation of biofilms of *S. aureus* MTCC 3160 by 13.29, 30.06, and 57.38%, respectively. At the highest tested concentration (64  $\text{TiO}_2$ -NPs), more than 80% inhibition was recorded. The bacteria growing in biofilms become many




Fig. 3 (A) Transmission electron micrograph of  $\text{TiO}_2$ -NPs recorded at 25000 $\times$  magnification and 200 kV. (B) Particles size distribution of  $\text{TiO}_2$ -NPs using TEM analysis. (C) EDX spectrum and histogram of weight% and atomic% distribution (inset).






Fig. 4 Effect of TiO<sub>2</sub>-NPs on the biofilm development of *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *E. coli* ATCC 25922 in absence and presence of TiO<sub>2</sub>-NPs. (A) Absorbances of the biofilm after staining with crystal violet. The data is presented as average of three independent replicates with standard deviation. The statistical significance was calculated using analysis variance (One-way ANOVA) and different letters above each group of the independent variables show that the groups are statistically different from one another at  $p$ -value = 0.05. (B) Percent inhibition of biofilms of *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *E. coli* ATCC 25922 by TiO<sub>2</sub>-NPs.

fold more resistant to chemotherapeutic agents that pose extra burden for the treatment of bacterial infections. For instance, it has been found that *P. aeruginosa* growing in biofilms on urinary catheters became up to 1000-folds more resistant to tobramycin compared to the planktonic growth.<sup>7</sup> The biofilms are important for clinical point of view and it has been estimated that a vast majority of bacterial infections involve biofilms formation for the establishment of successful infection.<sup>41</sup> Moreover, bacteria coordinate the expression of resistance genes and virulent traits in biofilms that makes poses difficulties for chemical as well as physical treatments.<sup>42</sup>

Antimicrobial resistance (AMR) or drug resistance poses a massive threat to public health and as well as the environment, where biofilms are considered as one of the major drivers in the dissemination of drug resistance. The aggregated bacterial communities in biofilms facilitate the transfer of resistant genes and also prevent the entry and diffusion of antibiotics.<sup>43</sup> Therefore, inhibition of development of biofilm using

nanoparticles is one of the promising approaches to prevent bacterial infection. Previously, bio-fabricated titanium oxide nanoparticles using *Ochradenus arabicus* have been found to inhibit the pathogenic biofilms of drug resistant *P. aeruginosa* and *S. aureus* isolated from diabetic foot infections.<sup>19</sup> It has been reported that silver nanoparticles embedding on copper surfaces reduced the viability of *E. coli* and *C. auris* by >90% on 7 days of exposure.<sup>44</sup> The galinstan (composed of gallium, indium, and tin) liquid metal particles with encapsulated iron were found to successfully reduce both the mono-species and multi-species biofilms.<sup>45</sup> It has been reported that extracts of *Carum copticum* poses good antibiofilm activity antibiotic-resistant bacteria.<sup>33</sup> It can be deduced that the antibiofilm activity of TiO<sub>2</sub>-NPs may be the synergistic or cumulative effects of both titanium nanoparticles and the phytoconstituents of *C. copticum*. The findings validate the broad-spectrum inhibition of biofilms by green synthesized titanium oxide nanoparticles.




Fig. 5 Light microscopic images showing the effect of TiO<sub>2</sub>-NPs on the biofilm development of test bacteria. (A) Control *E. coli* ATCC 25922; (B) *E. coli* ATCC 25922 treated with 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs; (C) control *P. aeruginosa* PAO1; (D) *P. aeruginosa* PAO1 treated with 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs; (E) control *S. aureus* MTCC 3160; (F) *S. aureus* MTCC 3160 treated with 64 µg ml<sup>-1</sup> TiO<sub>2</sub>-NPs.








Fig. 6 Confocal laser scanning microscopic images showing the effect of  $\text{TiO}_2$ -NPs on the biofilm development of test bacteria. (A) Control *E. coli* ATCC 25922; (B) *E. coli* ATCC 25922 treated with  $64 \mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs; (C) control *P. aeruginosa* PAO1; (D) *P. aeruginosa* PAO1 treated with  $64 \mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs.

### 3.4. Microscopic analysis of biofilms inhibition on glass surface using

The biofilm inhibition of test bacteria by  $\text{TiO}_2$ -NPs was further studied on a glass surface using an array of microscopic techniques such as using light microscopy, scanning electron microscopy, confocal microscopy, and the findings are discussed below.

The detailed analysis of changes in the biofilm's architecture by the treatment of  $\text{TiO}_2$ -NPs was studied by culturing the test bacteria in presence of  $\text{TiO}_2$ -NPs in 24-well tissue culture plates containing glass coverslips. The light microscopic images of control and treated test bacterial biofilms are shown in Fig. 5. The micrographs of untreated biofilms show that bacteria heavily colonized the glass surface and formed thick layer of biofilms. Treatment with  $\text{TiO}_2$ -NPs reduced the bacterial colonization and subsequently a remarkable inhibition in the biofilm development was observed.

The confocal laser scanning micrographs of untreated and treated bacterial biofilms of *P. aeruginosa* PAO1 and *E. coli* ATCC

25922 are shown in Fig. 6. As seen in control images, test bacteria formed very dense biofilms of glass coverslips. Dense clumps of cells in biofilms were found and bacteria were seen to be heavily colonized. However, the presence of  $\text{TiO}_2$ -NPs in culture media substantially reduced the biofilm formation and bacterial cells were found in scattered form. The result in agreement with the previous finding where a confocal microscopic analysis revealed that titanium oxide nanoparticles synthesized using *Withania somnifera* root extract inhibited the biofilms formation of *E. coli*, *P. aeruginosa*, *L. monocytogenes*, *S. marcescens*, and methicillin-resistant *S. aureus* (MRSA) on the glass surface.<sup>46</sup>

Further analysis of the alterations on the biofilm's architecture by the treatment of  $\text{TiO}_2$ -NPs was studied using scanning electron microscopy. The electron micrographs of control and  $\text{TiO}_2$ -NPs treated biofilms of test bacteria are shown in Fig. 7. The untreated *S. aureus* MTCC 3160 formed dense biofilms on a glass surface where the morphology of bacterial cells was




Fig. 7 Scanning electron microscopic images showing the effect of  $\text{TiO}_2$ -NPs on the biofilm development of test bacteria. (A) Control *E. coli* ATCC 25922; (B) *E. coli* ATCC 25922 treated with  $64 \mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs; (C) control *P. aeruginosa* PAO1; (D) *P. aeruginosa* PAO1 treated with  $64 \mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs; (E) control *S. aureus* MTCC 3160; (F) *S. aureus* MTCC 3160 treated with  $64 \mu\text{g ml}^{-1}$   $\text{TiO}_2$ -NPs. All images were captured at 2500 $\times$  magnification.



found to be normal and smooth. The bacterial cells were seen closed in extra polymeric substance. On contrary, treatment with TiO<sub>2</sub>-NPs reduced the biofilms formation with decreased bacterial colonization. Likewise, the development of the biofilm in control *P. aeruginosa* PAO1 was more than the treated one. The aggregation of bacteria on the glass surface was reduced in presence of TiO<sub>2</sub>-NPs that resulted in a fair decrease in the biofilm forming capability of *P. aeruginosa* PAO1. A similar observation was recorded for *E. coli* ATCC 25922 biofilms where challenging the bacteria with TiO<sub>2</sub>-NPs resulted in decreased biofilm formation. It is interesting to note that extra polymeric substances were not seen on the slides treated with TiO<sub>2</sub>-NPs. Hence, the microscopic analysis confirms the remarkable inhibition of biofilms of *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *P. aeruginosa* PAO1.

Most of the bacterial biofilms are pathogenic that cause nosocomial infections. As per National Institutes of Health (NIH) estimates, nearly 65% of all microbial infections and 80% of chronic infections are associated with biofilm development.<sup>47</sup> Hence, targeting biofilms, more precisely pathogenic biofilms, are considered as an effective strategy in the management of bacterial infections. Titanium oxide nanoparticles have been found previously to mitigate the biofilms of bacterial pathogens. The nanoparticles were synthesized leaves extract of *O. arabicus* that inhibited the biofilms of drug-resistant *P. aeruginosa* and *S. aureus* isolated from diabetic foot infections of the human subjects with diabetic foot ulcers.<sup>49</sup> Similarly, another study has found that biofabricated porous titanium dioxide nanoparticles synthesized using root extract of *Withania somnifera* exhibited a broad-spectrum antibiofilm activity against *P. aeruginosa*, *E. coli*, methicillin-resistant *S. aureus*, *S. marcescens*, *L. monocytogenes*, and *C. albicans*.<sup>46</sup> A study has found that surfaces coated with zinc oxide nanoparticles and ZnO/Ag nanocomposites selectively inhibited the biofilms of *E. coli*, *S. aureus*, and *C. albicans*.<sup>48</sup> Moreover, another study has documented that Ag/Cu/GO nanocomposite inhibited the biofilm formation of *P. aeruginosa* at the concentration which was harmless to human cells.<sup>49</sup> Our findings clearly show the ability of TiO<sub>2</sub>-NPs in inhibiting the biofilms of both Gram +ve and Gram -ve bacteria.

### 3.5. Inhibition of exopolysaccharides (EPS) production

Extracellular polymeric substances are natural polymers with a high molecular weight that provide structural framework to the biofilms.<sup>50</sup> Hence, extracellular polymeric substance is the fundamental component of biofilms and also determines the physicochemical properties. Among different constituents of extracellular polymeric substances, exopolysaccharides (EPS) are the major contributor.<sup>51</sup> EPS blocks the entry of chemotherapeutic agents, such as antibiotics, serving as a protective barrier for the bacterial cells.<sup>51</sup> The enhanced secretion of EPS alters the biofilm architecture and thereby confers drug resistance against antimicrobial agents.<sup>52</sup> There is a positive correlation between EPS secretion of biofilms formation, hence targeting EPS production is also considered as an alternate target for biofilms inhibition.<sup>53</sup> TiO<sub>2</sub>-NPs successfully inhibited the EPS secretion of test bacteria (Fig. 8A). The EPS secretion of *S. aureus* MTCC 3160 decreased by 11.66, 25.83, 37.20, and 54.27% by the treatment of 8, 16, 32, and 64 μg ml<sup>-1</sup> TiO<sub>2</sub>-NPs, respectively. Similarly, the presence of 8, 16, 32, and 64 μg ml<sup>-1</sup> TiO<sub>2</sub>-NPs reduced the EPS production of *E. coli* ATCC 25922 by 14.01, 26.56, 45.52, and 62.08%, respectively. The EPS formation of *P. aeruginosa* PAO1 was maximally inhibited (~75%) in presence of 64 μg ml<sup>-1</sup> TiO<sub>2</sub>-NPs. EPS is an important constituent of the biofilm's architecture. It provides structural stability to the biofilms and protects bacterial cells from antibiotics and environmental stresses.<sup>54</sup> Hence, targeting EPS is considered an alternative strategy to inhibit the biofilms as reduced secretion of EPS is expected to exert adverse effects on the biofilm-forming ability of bacterial pathogens. Porous titanium oxide nanoparticles synthesized using aqueous extract of *Withania somnifera* roots have been documented to inhibit the EPS production of methicillin-resistant *S. aureus*, *L. monocytogenes*, *P. aeruginosa*, *E. coli*, and *S. marcescens*.<sup>46</sup> Moreover, green synthesized silver nanoparticles have also been reported to inhibit the EPS secretion in *P. aeruginosa*, *S. aureus*, *K. pneumoniae*, and *C. albicans* in the presence of their respective inhibitory concentrations.<sup>30</sup>

### 3.6. Eradication of preformed biofilms

Most antibacterial drugs inhibit the planktonic mode of bacterial growth in which few of them are known to inhibit the




Fig. 8 (A) Inhibition of exopolysaccharides (EPS) secretion in *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *E. coli* ATCC 25922 by TiO<sub>2</sub>-NPs. (B) Disruption of established biofilms of *S. aureus* MTCC 3160, *P. aeruginosa* PAO1, and *E. coli* ATCC 25922 by TiO<sub>2</sub>-NPs. The data is presented as average of three independent replicates with standard deviation. The statistical significance was calculated using analysis variance (One-way ANOVA) and different letters above each group of the independent variables show that the groups are statistically different from one another at  $p$ -value = 0.05.





development of biofilm.<sup>55</sup> Inhibition of biofilms is relatively easier compared to the eradication of established biofilms. In most successful infections, the biofilms get established at the site of infection. In this assay, the bacterial strains were allowed to form the biofilms in 96-well microtitre plates followed by treating the established biofilms. The effect of TiO<sub>2</sub>-NPs on the removal of preformed biofilms is shown in Fig. 8B. The presence of 8, 16, 32, and 64 μg ml<sup>-1</sup> TiO<sub>2</sub>-NPs eradicated the established biofilms of *P. aeruginosa* PAO1 by 17.77, 31.85, 48.77, and 64.14%, respectively. Similarly, the preformed biofilms of *E. coli* ATCC 25922 were decreased by 12.11, 35.23, 45.99, and 60.09%, respectively. TiO<sub>2</sub>-NPs exhibited the least effect on established biofilms of *S. aureus* MTCC 3160 where the presence of 64 μg ml<sup>-1</sup> disrupted the biofilms by 48.30%. The data demonstrate the successful biofilm eradication of the test bacteria. Bacterial biofilms are the clump of bacterial cells embedded in extracellular polymeric substances.<sup>56</sup> The major component of extracellular polymeric substances are polysaccharides, nucleic acids, and polypeptides along with some other biochemical components.<sup>57</sup> These components act as a barrier for the entry of chemotherapeutic agents.<sup>58</sup> Our findings are in agreement with the previous report in which the established biofilms of *P. aeruginosa*, *E. coli*, methicillin-resistant *S. aureus*, and *L. monocytogenes* were disrupted by 65, 45, 64, and 49%, respectively.<sup>46</sup> A study conducted on silver nanoparticles has found that silver nanoparticles can diffuse the biofilms matrix.<sup>59</sup> It can be deduced that TiO<sub>2</sub>-NPs may be able to penetrate the established biofilms that resulted in disruption of biofilms. The extract of *C. copticum* are documented to disrupt the preformed biofilms of *B. cereus*, *S. aureus*, *P. aeruginosa*, *E. coli*, *A. baumannii*, and *K. pneumoniae*.<sup>33</sup> The eradication of biofilms may also be attributed to the cumulative effects of both titanium nanoparticles and the phyto-compounds of *C. copticum*. The results show that TiO<sub>2</sub>-NPs were successful both in the inhibition as well as eradication of the biofilms of test bacteria.

## 4. Conclusion

Biofilms have great implications both in clinical settings and the environment. The majority of successful bacterial infections are associated and influenced by biofilms development. Here, we have synthesized titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs) using *Carum copticum* extract and tested its ability to inhibit the development of biofilm. The nanoparticles were spherical or spheroidal in shape with an average size of 12.01 nm. More than 70% reduction in biofilms formation of the bacteria was found by the treatment of TiO<sub>2</sub>-NPs. Microscopic analysis of the biofilms deciphered that bacterial adherence and colonization on a solid support (glass surface) was remarkably hampered in presence of TiO<sub>2</sub>-NPs. The EPS secretion of test bacteria was also inhibited dose-dependently. TiO<sub>2</sub>-NPs was quite efficient in removing the established biofilms of *E. coli* ATCC 25922, *P. aeruginosa* PAO1, and *S. aureus* MTCC 3160. The data shows the potency of TiO<sub>2</sub>-NPs against biofilms of bacterial pathogens and it can be exploited further for the development of novel alternative antibiofilm agents.

## Abbreviation

TiO <sub>2</sub> -NPs	Titanium dioxide nanoparticles
EPS	Exopolysaccharides
FTIR	Fourier transforms infrared
TEM	Transmission electron microscopy
SEM	Scanning electron microscopy
UV-vis	UV-visible
XRD	X-ray diffraction
EDX	Energy-dispersive X-ray

## Conflicts of interest

The authors declare that they have no conflict of interest.

## Acknowledgements

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the research group project number RG-1439-076.

## References

- 1 J. Costerton, G. Geesey and K. J. Cheng, *Sci. Am.*, 1978, **238**, 86–95.
- 2 C. A. Fux, J. W. Costerton, P. S. Stewart and P. Stoodley, *Trends Microbiol.*, 2005, **13**, 34–40.
- 3 L. Hall-Stoodley and P. Stoodley, *Trends Microbiol.*, 2005, **13**, 7–10.
- 4 R. M. Donlan and J. W. Costerton, *Clin. Microbiol. Rev.*, 2002, **15**, 167–193.
- 5 T. Bjarnsholt, M. Alhede, P. Ø. Jensen, A. K. Nielsen, H. K. Johansen, P. Homøe, N. Høiby, M. Givskov and K. Kirketerp-Møller, *Adv. Wound Care*, 2015, **4**, 363–372.
- 6 A. Foreman, G. Holtappels, A. J. Psaltis, J. Jarvis-Bardy, J. Field, P.-J. Wormald and C. Bachert, *Allergy*, 2011, **66**, 1449–1456.
- 7 J. C. Nickel, I. Ruseska, J. B. Wright and J. W. Costerton, *Antimicrob. Agents Chemother.*, 1985, **27**, 619–624.
- 8 L. Hall-Stoodley, P. Stoodley, S. Kathju, N. Høiby, C. Moser, J. William Costerton, A. Moter and T. Bjarnsholt, *FEMS Immunol. Med. Microbiol.*, 2012, **65**, 127–145.
- 9 M. K. Yadav, J.-J. Song, B. P. Singh and J. E. Vidal, in *New and Future Developments in Microbial Biotechnology and Bioengineering: Microbial Biofilms*, Elsevier, 2020, pp. 1–13.
- 10 S. Veerachamy, T. Yarlagadda, G. Manivasagam and P. K. Yarlagadda, *Proc. Inst. Mech. Eng., Part H*, 2014, **228**, 1083–1099.
- 11 S. L. Percival, *Br. J. Surg.*, 2017, **104**, e85–e94.
- 12 J. P. S. Woods, E. J. Davis and P. Barnett, in *Microbiology of Wounds*, CRC Press, London, 2010, pp. 271–92.
- 13 D. D. Rhoads, R. D. Wolcott and S. L. Percival, *Journal of Wound Care*, 2008, **17**, 502–508.



- 14 J. V. Rau, R. De Santis and G. Ciofani, *Bioact. Mater.*, 2017, **2**, 119–120.
- 15 V. Bhardwaj and A. Kaushik, *Micromachines*, 2017, **8**, 298.
- 16 C. K. Tagad, S. R. Dugasani, R. Aiyer, S. Park, A. Kulkarni and S. Sabharwal, *Sens. Actuators, B*, 2013, **183**, 144–149.
- 17 E. S. Abdel-Halim, M. H. El-Rafie and S. S. Al-Deyab, *Carbohydr. Polym.*, 2011, **85**, 692–697.
- 18 A. R. Lokanathan, K. M. A. Uddin, O. J. Rojas and J. Laine, *Biomacromolecules*, 2014, **15**, 373–379.
- 19 M. Zubair, F. M. Husain, F. A. Qais, P. Alam, I. Ahmad, T. Albalawi, N. Ahmad, M. Alam, M. H. Baig, J.-J. Dong, F. Fatima and B. Alsayed, *Appl. Nanosci.*, 2021, **11**, 375–387.
- 20 A. J. Haider, Z. N. Jameel and I. H. M. Al-Hussaini, *Energy Procedia*, 2019, **157**, 17–29.
- 21 E. H. Abdulkareem, K. Memarzadeh, R. P. Allaker, J. Huang, J. Pratten and D. Spratt, *J. Dent.*, 2015, **43**, 1462–1469.
- 22 N. A. Al-Shabib, F. M. Husain, I. Hassan, M. S. Khan, F. Ahmed, F. A. Qais, M. Oves, M. Rahman, R. A. Khan, A. Khan, A. Hussain, I. M. Alhazza, S. Aman, S. Noor, H. Ebaid, J. Al-Tamimi, J. M. Khan, A. R. M. Al-Ghadeer, M. K. A. Khan and I. Ahmad, *J. Nanomater.*, 2018, **2018**, 1–14.
- 23 N. A. Al-Shabib, F. M. Husain, N. Ahmad, F. A. Qais, A. Khan, A. Khan, M. S. Khan, J. M. Khan, S. A. Shahzad and I. Ahmad, *J. Nanomater.*, 2018, **2018**, 1–11.
- 24 A. S. Ahmed, A. Iqbal, A. Shafi, F. A. Qais, T. Ahamad and S. Srivastava, *J. Cluster Sci.*, 2020, **77**, 1–7.
- 25 F. M. Husain, I. Hasan, F. A. Qais, R. A. Khan, P. Alam and A. Alsalmeh, *Coatings*, 2020, **10**, 1190.
- 26 G. A. O'Toole and R. Kolter, *Mol. Microbiol.*, 1998, **30**, 295–304.
- 27 F. A. Qais, A. Shafiq, I. Ahmad, F. M. Husain, R. A. Khan and I. Hassan, *Microb. Pathog.*, 2020, **144**, 104172.
- 28 M. Maheshwari, F. A. Qais, A. S. Althubiani, H. H. Abulreesh and I. Ahmad, *Biofouling*, 2019, **35**, 1026–1039.
- 29 F. A. Qais, M. S. Khan and I. Ahmad, *Microb. Pathog.*, 2019, **126**, 379–392.
- 30 I. Hasan, F. A. Qais, F. M. Husain, R. A. Khan, A. Alsalmeh, B. Alenazi, M. Usman, M. H. Jaafar and I. Ahmad, *J. Cleaner Prod.*, 2019, **230**, 1148–1155.
- 31 M. DuBois, K. A. Gilles, J. K. Hamilton, P. A. Rebers and F. Smith, *Anal. Chem.*, 1956, **28**, 350–356.
- 32 F. A. Qais, Samreen and I. Ahmad, *IET Nanobiotechnol.*, 2018, **12**, 325–335.
- 33 M. Mohammadi, F. Masoumpour, M. Hassanshahian and T. Jafarinasab, *Microb. Pathog.*, 2019, **129**, 99–105.
- 34 V. Sivaranjani and P. Philominathan, *Wound Medicine*, 2016, **12**, 1–5.
- 35 T. Santhoshkumar, A. A. Rahuman, C. Jayaseelan, G. Rajakumar, S. Marimuthu, A. V. Kirthi, K. Velayutham, J. Thomas, J. Venkatesan and S.-K. Kim, *Asian Pac. J. Trop. Med.*, 2014, **7**, 968–976.
- 36 S. Subhapiya and P. Gomathipriya, *Microb. Pathog.*, 2018, **116**, 215–220.
- 37 M. Sundrarajan and S. Gowri, *Chalcogenide Lett.*, 2011, **8**, 447–451.
- 38 W. Ahmad, K. K. Jaiswal and S. Soni, *Inorg. Nano-Met. Chem.*, 2020, **50**, 1032–1038.
- 39 A. A. Zahir, I. S. Chauhan, A. Bagavan, C. Kamaraj, G. Elango, J. Shankar, N. Arjaria, S. M. Roopan, A. A. Rahuman and N. Singh, *Antimicrob. Agents Chemother.*, 2015, **59**, 4782–4799.
- 40 G. Rajakumar, A. A. Rahuman, B. Priyamvada, V. G. Khanna, D. K. Kumar and P. J. Sujin, *Mater. Lett.*, 2012, **68**, 115–117.
- 41 B. Schachter, *Nat. Biotechnol.*, 2003, **21**, 361–365.
- 42 A. Pompilio, V. Crocetta, S. De Nicola, F. Verginelli, E. Fiscarelli and G. Di Bonaventura, *Front. Microbiol.*, 2015, **6**, 951.
- 43 J. L. Balcázar, J. Subirats and C. M. Borrego, *Front. Microbiol.*, 2015, **6**, 1216.
- 44 S. Gangadoo, A. Elbourne, A. E. Medvedev, D. Cozzolino, Y. B. Truong, R. J. Crawford, P.-Y. Wang, V. K. Truong and J. Chapman, *Coatings*, 2020, **10**, 28.
- 45 S. Cheeseman, A. Elbourne, R. Kariuki, A. V. Ramarao, A. Zavabeti, N. Syed, A. J. Christofferson, K. Y. Kwon, W. Jung, M. D. Dickey, K. Kalantar-Zadeh, C. F. McConville, R. J. Crawford, T. Daeneke, J. Chapman and V. K. Truong, *J. Mater. Chem. B*, 2020, **8**, 10776–10787.
- 46 N. A. Al-Shabib, F. M. Husain, F. A. Qais, N. Ahmad, A. Khan, A. A. Alyousef, M. Arshad, S. Noor, J. M. Khan, P. Alam, T. H. Albalawi and S. A. Shahzad, *Front. Microbiol.*, 2020, **11**, 1680.
- 47 M. Jamal, W. Ahmad, S. Andleeb, F. Jalil, M. Imran, M. A. Nawaz, T. Hussain, M. Ali, M. Rafiq and M. A. Kamil, *J. Chin. Med. Assoc.*, 2018, **81**, 7–11.
- 48 M. Rosenberg, M. Visnapuu, H. Vija, V. Kisand, K. Kasemets, A. Kahru and A. Ivask, *Sci. Rep.*, 2020, **10**, 13478.
- 49 J. Jang, J.-M. Lee, S.-B. Oh, Y. Choi, H.-S. Jung and J. Choi, *ACS Appl. Mater. Interfaces*, 2020, **12**, 35826–35834.
- 50 E. Maunders and M. Welch, *FEMS Microbiol. Lett.*, 2017, **364**, DOI: 10.1093/femsle/fnx120.
- 51 K. Sauer and A. K. Camper, *J. Bacteriol.*, 2001, **183**, 6579–6589.
- 52 F. H. Yildiz and G. K. Schoolnik, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 4028–4033.
- 53 K. Czaczyk and K. Myszka, *Pol. J. Environ. Stud.*, 2007, **16**, 799–806.
- 54 H.-C. Flemming, T. R. Neu and D. J. Wozniak, *J. Bacteriol.*, 2007, **189**, 7945–7947.
- 55 R. Roy, M. Tiwari, G. Donelli and V. Tiwari, *Virulence*, 2018, **9**, 522–554.
- 56 Y. Li, P. Xiao, Y. Wang and Y. Hao, *ACS Omega*, 2020, **5**, 22684–22690.
- 57 L. Karygianni, Z. Ren, H. Koo and T. Thurnheer, *Trends Microbiol.*, 2020, **28**, 668–681.
- 58 N. Høiby, O. Ciofu, H. K. Johansen, Z. Song, C. Moser, P. Ø. Jensen, S. Molin, M. Givskov, T. Tolker-Nielsen and T. Bjarnsholt, *Int. J. Oral Sci.*, 2011, **3**, 55–65.
- 59 T. O. Peulen and K. J. Wilkinson, *Environ. Sci. Technol.*, 2011, **45**, 3367–3373.

